• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Heartbeam Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    7/16/25 2:15:18 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care
    Get the next $BEAT alert in real time by email
    false 0001779372 0001779372 2025-07-11 2025-07-11 0001779372 us-gaap:CommonStockMember 2025-07-11 2025-07-11 0001779372 us-gaap:WarrantMember 2025-07-11 2025-07-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): July 11, 2025

     

    HEARTBEAM, INC.

    (Exact name of Registrant as specified in its charter)

     

    Delaware   001-41060   47-4881450
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    2118 Walsh Avenue, Suite 210

    Santa Clara, CA 95050

    (Address of principal executive offices, including zip code)

     

    (408) 899-4443

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

     

    ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock   BEAT   NASDAQ
    Warrant   BEATW   NASDAQ

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

     

     

     

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders

     

    On July 11, 2025, HeartBeam, Inc. (the “Company”) held an annual meeting of stockholders (the “Annual Meeting”) virtually, via live webcast.

     

    As of the close of business on May 12, 2025, the record date for the Annual Meeting (the “Record Date”), 33,809,707 shares of the Company’s common stock, par value $0.0001 (the “Common Stock”) were outstanding and entitled to vote. At the Annual Meeting, a total of 18,702,366 votes, comprised of shares of the Company’s Common Stock, equivalent to approximately 55.32% of the outstanding votes, were represented in person or by proxy at the Annual Meeting, constituting a quorum. The matters that were voted upon at the Annual Meeting, and the number of votes cast for or against/withheld, as well as the number of abstentions and broker non-votes, as to such matters, where applicable, are set forth below.

     

    1. The nine nominees for director were elected to serve a one-year term as follows:

     

    Director  Votes For   Votes
    Against
       Abstain   Broker
    Non-Vote
     
    Richard Ferrari  6,796,276   237,566   88,764   11,579,760 
    Branislav Vajdic, PhD  6,971,395   64,960   86,251   11,579,760 
    George A. de Urioste  6,748,429   165,710   208,467   11,579,760 
    Marga Ortigas-Wedekind  5,153,730   1,878,916   89,960   11,579,760 
    Willem Elfrink  6,867,987   162,120   92,499   11,579,760 
    Mark Strome  5,499,488   1,531,719   91,399   11,579,760 
    Kenneth Nelson  6,996,326   36,889   89,391   11,579,760 
    Michael Jaff  6,992,884   37,023   92,699   11,579,760 
    Robert Eno  6,995,306   41,109   86,191   11,579,760 

     

    2. The proposal to ratify the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, was approved as follows:

     

    Votes For   Votes Against   Broker Non-Votes   Votes Abstained 
    18,388,997   55,859   0   257,510 

     

    3. The proposal to amend the 2022 Equity Incentive Plan to increase the number of authorized shares from 8,900,000 shares to 11,900,000 shares:

     

    Votes For   Votes Against   Broker Non-Votes   Votes Abstained 
    4,375,827   2,717,474   11,579,760   29,305 

     

    Item 9.01 Financial Statements and Exhibits 

     

    (d) Exhibits.

     

    Exhibit
    Number
      Description
    10.1   Third Amendment to the HeartBeam, Inc. 2022 Equity Incentive Plan
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

     

      HeartBeam, Inc.
         
    Date: July 16, 2025   /s/ Timothy Cruickshank
      Name: Timothy Cruickshank
      Title: Chief Financial Officer

     

    2

     

    Get the next $BEAT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BEAT

    DatePrice TargetRatingAnalyst
    3/16/2026$8.00Buy → Speculative Buy
    The Benchmark Company
    12/11/2025$8.00Speculative Buy → Buy
    The Benchmark Company
    12/8/2025$2.50Buy
    H.C. Wainwright
    10/31/2025$4.00Buy
    Roth Capital
    12/20/2021$9.00Speculative Buy
    Benchmark
    More analyst ratings

    $BEAT
    SEC Filings

    View All

    SEC Form EFFECT filed by Heartbeam Inc.

    EFFECT - HeartBeam, Inc. (0001779372) (Filer)

    3/18/26 12:15:08 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form S-3/A filed by Heartbeam Inc.

    S-3/A - HeartBeam, Inc. (0001779372) (Filer)

    3/13/26 5:14:36 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Heartbeam Inc.

    10-K - HeartBeam, Inc. (0001779372) (Filer)

    3/12/26 4:02:59 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HeartBeam Reports Fourth Quarter and Full Year 2025 Results

    HeartBeam Enters New Growth Phase Following FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment First Commercial Partner ClearCardio™ to Bring HeartBeam's 3D ECG Technology to High-Growth Preventive Cardiology Market First Patients Enrolled in Heart Attack Detection Pilot Study, A Key Step Toward Future FDA Indication Expansion Completed the First Working Prototype of an Extended-Wear 12-Lead ECG Patch Strategic Collaboration with the Icahn School of Medicine at Mount Sinai to Accelerate Next-Generation AI-ECG Algorithms Management to Host Webcast and Conference Call Today at 4:30 p.m. ET   HeartBeam, Inc. (NASDAQ:BEAT), a

    3/12/26 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam and Mount Sinai Announce Strategic AI Collaboration to Bring Clinical-Grade Heart Monitoring into the Home

    Accelerates development of personalized cardiac AI on the HeartBeam platform for wellness and clinical applications, including assessing heart attack risk Combines Mount Sinai's world-class AI and clinical expertise with HeartBeam's groundbreaking 3D ECG signal collection technology HeartBeam is the only platform capable of collecting 12-lead ECG data from patients anytime, anywhere, over time – extending access beyond traditional clinical settings Positions HeartBeam to expand from symptom-based cardiac rhythm monitoring into AI-enabled disease assessment and management HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providin

    3/10/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam to Attend Investor and Industry Conferences in March, Focused on Providing Updates on Commercial Launch and Unveiling 12-Lead ECG Extended Wear Patch

    HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that management will attend key investor and industry conferences in March 2026. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will attend the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, 2026. Management will host a presentation webcast on March 16 at 11:20 a.m. Eastern time (8:20 a.m. Pacific time) and host one-on-one meetings with institutional and retail investors. Mr. Eno and Mr. Cruickshank will also attend the 38th Annual ROTH Conference taking place in Dana Point, California in

    3/9/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HeartBeam downgraded by The Benchmark Company with a new price target

    The Benchmark Company downgraded HeartBeam from Buy to Speculative Buy and set a new price target of $8.00

    3/16/26 8:51:28 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded HeartBeam from Speculative Buy to Buy and set a new price target of $8.00

    12/11/25 8:45:10 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright initiated coverage on HeartBeam with a new price target

    H.C. Wainwright initiated coverage of HeartBeam with a rating of Buy and set a new price target of $2.50

    12/8/25 8:34:44 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Strome Mark E sold $895,000 worth of shares (250,000 units at $3.58) (SEC Form 4)

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    12/22/25 5:44:34 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Director De Urioste George sold $182,090 worth of shares (57,146 units at $3.19), closing all direct ownership in the company (SEC Form 4)

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    12/19/25 5:10:19 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by CFO Cruickshank Tim

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    10/3/25 4:36:53 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ferrari Richard bought $50,000 worth of shares (29,412 units at $1.70), increasing direct ownership by 20% to 179,136 units (SEC Form 4)

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    2/21/25 8:00:22 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    CFO Cruickshank Tim bought $30,000 worth of shares (17,647 units at $1.70) (SEC Form 4)

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    2/21/25 7:55:14 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Leadership Updates

    Live Leadership Updates

    View All

    HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer

    Brings more than 25 years of experience in building and scaling groundbreaking cardiovascular technologies Will initially focus on launching the Company's FDA-cleared 12-lead ECG system for arrhythmia assessment Will lead the Company's broader commercialization strategy across key growth initiatives, including heart attack detection and the 12-lead ECG extended-wear patch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In this newly created role, Mr. Humbarger will lead commercial strate

    1/22/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth

    Board expansion reflects Company's commitment to leadership and innovation in remote cardiac monitoring HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the appointment of Chief Executive Officer, Robert Eno, to its Board of Directors. As the Company continues to make significant advancements towards commercial readiness, the Board elected to expand from eight to nine members to accommodate this addition. Mr. Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. With over 30 years of experience in the medical technology industry, he has a proven

    5/5/25 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology

    First cable-free, ambulatory ECG that captures the heart's electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device with them at all times, ready to record an ECG whenever they feel symptoms and reduce delays in care Company to initiate Early Access Program to gain important patient and physician feedback on the use of the system in preparation for commercial launch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the US Food and Drug Administration (FDA) has granted 510(k) cl

    12/16/24 8:31:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Financials

    Live finance-specific insights

    View All

    HeartBeam Reports Fourth Quarter and Full Year 2025 Results

    HeartBeam Enters New Growth Phase Following FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment First Commercial Partner ClearCardio™ to Bring HeartBeam's 3D ECG Technology to High-Growth Preventive Cardiology Market First Patients Enrolled in Heart Attack Detection Pilot Study, A Key Step Toward Future FDA Indication Expansion Completed the First Working Prototype of an Extended-Wear 12-Lead ECG Patch Strategic Collaboration with the Icahn School of Medicine at Mount Sinai to Accelerate Next-Generation AI-ECG Algorithms Management to Host Webcast and Conference Call Today at 4:30 p.m. ET   HeartBeam, Inc. (NASDAQ:BEAT), a

    3/12/26 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam to Host Fourth Quarter Full Year 2025 Results Conference Call on Thursday, March 12, 2026 at 4:30 p.m. Eastern Time

    HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, March 12, 2026 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2025, and will be providing updates on its key strategic growth initiatives, specifically the limited commercial launch and significant developments on the 12-lead ECG extended wear patch. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. They will

    3/4/26 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Reports Third Quarter 2025 Results

    Commercial Readiness Plans Accelerating in Anticipation of FDA 510(k) Clearance for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software for Arrhythmia Assessment Anticipated FDA Clearance in Q4 2025 is a Major Inflection Point as HeartBeam Evolves into a Commercial-Stage Company Focused on Growth Announced Partnership with HeartNexus to Provide On-Demand Cardiologist Reviews of Synthesized 12-Lead ECGs for Arrhythmia Assessment and Triage Patients Data Presented at AHA Scientific Sessions and HRX Live 2025 Continue to Advance HeartBeam's Pipeline for Ischemia Detection and Deep Learning Algorithms Management to Host Webcast and Conference Call Today at 4:30 p.m. E

    11/13/25 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Heartbeam Inc.

    SC 13D - HeartBeam, Inc. (0001779372) (Subject)

    10/25/23 4:01:55 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by Heartbeam Inc.

    SC 13D - HeartBeam, Inc. (0001779372) (Subject)

    8/28/23 4:26:34 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by Heartbeam Inc.

    SC 13D - HeartBeam, Inc. (0001779372) (Subject)

    6/2/23 2:36:13 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care